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Abstract
Purpose Osteoarticular infections due to methicillin-
susceptible Staphylococcus aureus (MSSA) or its
methicillin-resistant variant (MRSA) are feared due to
treatment failures. According to clinical experience, Pseu-
domonas aeruginosa may reveal less long-term remission
than S. aureus.
Methods A case-controlled study comparing outcomes of
osteoarticular infections due to P. aeruginosa vs S. aureus
was performed at Geneva University Hospitals.
Results A total of 111 S. aureus (including 37 MRSA) and
20 P. aeruginosa osteoarticular infections were analysed in
131 patients: arthroplasties (n=38), fracture fixation devi-
ces (n=56), native joint arthritis (n=7) and osteomyelitis
without implant (n=30). The median active follow-up time
was 4 years. The patients underwent a median number of
two surgical interventions for P. aeruginosa infections
compared to two for S. aureus (two for MRSA), while the
median duration of antibiotic treatment was 87 days for P.
aeruginosa and 46 days for S. aureus infections (58 days
for MRSA) (all p>0.05). Overall, Pseudomonas-infected
patients tended towards a lower remission rate than those
infected with S. aureus (12/20 vs 88/111; p=0.06). This
was similar when P. aeruginosa was compared with MRSA
alone (12/20 vs 30/37; p=0.08). In multivariate logistic
regression analyses adjusting for case mix, odds ratios (OR)
for remission were as follows: P. aeruginosa vs S. aureus
[OR 0.4, 95% confidence interval (CI) 0.1–1.2], number of
surgical interventions (OR 0.6, 95% CI 0.5–1.0) and
duration of antibiotic treatment (OR 1.0, 95% CI 1.0–1.0).
Conclusions Despite a similar number of surgical interven-
tions and longer antibiotic treatment, osteoarticular infec-
tions due to P. aeruginosa tended towards a lower
remission rate than infections due to S. aureus in general
or MRSA in particular.
Introduction
Staphylococcus aureus comprises up to two thirds of all
pathogens in osteoarticular infections [1], which are
difficult to treat because of the organism’s ability to form
small colony variants and to grow into biofilms [2]. In a
recent report comparing the outcomes of orthopaedic
implant infections due to methicillin-susceptible S. aureus
(MSSA), methicillin-resistant S. aureus (MRSA) and
coagulase-negative staphylococci, overall remission was
worst for MRSA (57%), followed by MSSA (72%) and
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best for coagulase-negative staphylococci (82%) [3]. Kilgus
et al. showed that hip arthroplasties infected due to MRSA
were treated successfully in only 48% of cases, as
compared to 81% with MSSA infection [4]. Salgado et al.
attributed a ninefold higher ratio for treatment failure in
prosthetic joint infections due to MRSA than due to MSSA
[5]. The surgical and medical literature is full of publica-
tions regarding staphylococcal osteoarticular infections,
especially for MRSA.
In contrast, Pseudomonas aeruginosa is an under-reported
Gram-negative pathogen in the orthopaedic domain. P.
aeruginosa is at least as clinically virulent as S. aureus and
also readily forms biofilms [6, 7] using extensive quorum-
sensing abilities [8], develops resistance to administered
antibiotics more rapidly than S. aureus and produces a large
variety of virulence factors such as type III secretion-
dependent cytotoxicity [7, 8]. Unsurprisingly, P. aeruginosa
is feared by orthopaedic surgeons and infectious disease
specialists with experience in osteoarticular infections. Many
of them would attribute a worse prognosis for pseudomonal
bone and joint infections compared to S. aureus.
However, there is little literature about P. aeruginosa and
osteoarticular infections. P. aeruginosa accounts for an
absolute minority of all osteoarticular pathogens [1], and
most reports are either case series involving around 20–30
cases [9–13] or even less [14–27]. Moreover, these reports
subsume P. aeruginosa under other Gram-negative patho-
gens [9, 12, 13, 19], including anaerobes [10, 28], and lack
adjustment for case mix [9, 10, 19, 21]. Often, outcome
comparisons of osteoarticular infections due to P. aerugi-
nosa with Gram-positive pathogens are almost non-existent
[10, 28]. Hsieh et al. retrospectively compared arthroplasty
infections due to Gram-positive pathogens to the same
infections due to Gram-negative pathogens. They found
that conservative treatment of Gram-negative infection by
debridements was associated with a lower success rate than
treating Gram-positive arthroplasty infections (27 vs 47%
remission). However, this difference vanished when a two-
stage exchange was performed [10].
In this clinical case-control study, we investigate the
hypothesis of lower remission risks of pseudomonal osteo-
articular infections compared to S. aureus (the most
frequent pathogen) and MRSA (the pathogen with the most
frequent treatment relapses known so far) by adjusting for
case mix of the underlying complex patient population.
Methods
Setting and data collection
The Orthopedic Service of Geneva University Hospitals is a
tertiary centre with a septic subunit consisting of 22 acute
care beds. A dedicated team of orthopaedic surgeons,
infectious disease specialists, diabetologists, nurses and
physiotherapists treat patients with osteoarticular infections
[29].
Prospectively registered databases from the arthroplasty
cohort and septic orthopaedic cohort were searched for
osteoarticular infections among adult orthopaedic patients
from January 1996 to November 2009. Patients were
followed up to 31 July 2011. Forty-two variables for each
episode were assessed related to demographic character-
istics, immunosuppression, microbiology, surgical and
antibiotic treatment modalities and outcomes. The quanti-
tative microbiological procedures were unchanged during
the study period and based on the Clinical and Laboratory
Standards Institute (CLSI) guidelines [30] and in-house
MRSA identification methods [3]. No typing was per-
formed. Since clinical specimens had not been stored, no
retrospective analyses of minimal inhibitory concentrations
could be performed. The study was supported by the local
Ethics Committee (No. 08-017R; 08-029R).
Criteria and definitions
Definition of osteoarticular infection required local signs of
infection such as heat, erythema, pus or functional
impairment; a medical report; a targeted antibiotic treat-
ment; and the presence of the same pathogen in at least
three intra-operative samples. In order to enhance specific-
ity, only cultures which were grown on plates were
considered. Co-pathogens were accepted only if S. aureus
or P. aeruginosa outnumbered them by at least threefold in
intra-operative microbiological specimens, for instance
coagulase-negative staphylococci (103 cfu/ml) in one
specimen and P. aeruginosa in all four specimens. Only
the first episode of bone and joint infection per patient was
included; patients presenting with relapsing episodes were
excluded. Further exclusion criteria were paediatric patients
(≤ 16 years), cure by amputation, involvement of fingers or
toes only and a minimal active follow-up of less than
18 months after end of treatment.
Remission was defined as complete clinical and labora-
tory resolution of the former infection. Immunosuppressed
patients were considered those with active neoplasm,
insulin-dependent diabetes mellitus, Child class C cirrhosis,
dialysis or those requiring chronic steroid therapy (prednis-
olone equivalence of 15 mg/day). Multi-resistance among
P. aeruginosa strains meant resistance to at least four
classes of antibiotic agents.
Statistical analyses
Group comparisons were performed using the Pearson χ2
test, Fisher’s exact test or the Wilcoxon rank sum test, as
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appropriate. Logistic regression analyses determined asso-
ciations with remission. Independent variables with a p
value ≤0.2 in univariate analysis were added stepwise in the
multivariate analysis to adjust for case mix. We included
five to ten predictor variables per outcome event [31]. The
following variables were introduced into the final model
independently of their association in univariate analysis: P.
aeruginosa vs S. aureus, age, duration of antibiotic
treatment and number of surgical interventions. Since
comparison of P. aeruginosa with S. aureus (MSSA &
MRSA) might be different from the comparison of P.
aeruginosa with MRSA alone, all analyses were repeated
for S. aureus and MRSA separately. Key variables were
checked for collinearity and interaction, the latter by
Mantel-Haenszel estimates. A p value≤0.05 (two-tailed)
was considered significant. Stata software (9.0, StataCorp.,
College Station, TX, USA) was used.
Results
Infections and patients
A total of 131 episodes of osteoarticular infections in 131
adult orthopaedic patients were retrieved. The median age
was 63 years and 53 were women. Thirty-seven patients
(28%) were immunocompromised: 17 due to diabetes
mellitus, nine by advanced cirrhosis due to alcoholism,
one by dialysis, one by cancer and nine by chronic steroid
medication. The infected implants in the arthroplasty group
included total hip (n=22) and total knee (n=16) prostheses.
In the fracture fixation devices group, the infected implants
included plates (n=28), intramedullary nails (n=14),
external fixation devices (n=7), hip screws (n=3), other
screws (n=2), patellar cerclage wire (n=1) and spondylod-
esis material (n=1). Additionally, we retrieved seven
episodes of septic native joint arthritis and 30 episodes of
osteomyelitis without implant. Crude group comparisons of
demographic and treatment characteristics according to the
pathogen are displayed in Table 1.
Pathogens
According to study definitions, we included osteoarticular
infections due to S. aureus and P. aeruginosa only. With
111 infectious episodes, S. aureus was overwhelmingly
predominant compared to P. aeruginosa (20 episodes). In
37 cases, S. aureus was resistant to methicillin. In 21 S.
aureus infections, there was a co-pathogen with at
minimum a threefold lesser quantitative growth in cultures:
coagulase-negative staphylococci (four), streptococci (sev-
en), Proteus spp. (five), Klebsiella spp. (two), Escherichia
coli (one), Enterobacter cloacae (one) and Enterococcus
faecalis (one). Co-pathogens were seen in six pseudomonal
infections: coagulase-negative staphylococci (four), Enter-
obacter spp. (one) and Klebsiella spp. (one). With the
exception of two multi-resistant P. aeruginosa episodes, all
pseudomonal infections were susceptible to most antipseu-
domonal antibiotic agents, 11 of which were susceptible to
every antipseudomonal antibiotic tested.
Among the S. aureus cases, all but two were surgical site
infections, while the origin of P. aeruginosa infections was
heterogeneous: open fractures (seven), surgical site infec-
tions (five), haematogenous infections (two; one of which
was in a patient with sickle cell anaemia), IV drug abuse
(one), unknown (two) and pressure ulcer (three). Two
patients had prior empiric antibiotic therapy before diagno-
sis. We failed to establish epidemiological links between
the different cases of pseudomonal or MRSA infections.
Surgical treatment
All patients underwent surgical treatment with a median of
two surgical interventions in the operating theatre (range
one to six surgeries). Pseudomonal and staphylococcal
surgical treatments did not differ in the number of
interventions (median two vs two interventions, p=0.43)
(Table 1).
Antibiotic treatment
All patients received systemic antibiotic therapy. No anti-
biotics or detergents [32] were added to the irrigating
solutions. Gentamicin beads were used in six cases (three
for S. aureus and three for P. aeruginosa) for a median
duration of three weeks. The median duration of total
antibiotic therapy was eight weeks (range six–14 weeks) for
the entire study population. The median duration of
antibiotic treatment tended to be longer for P. aeruginosa
(87 days), compared to 46 days for S. aureus infections,
and 58 days for MRSA, although the differences were not
significant (all p>0.05) (Table 1).
There were no clear preferences for the choice of
antibiotic agents. For staphylococcal parenteral therapy,
flucloxacillin, amoxicillin/clavulanic acid and vancomycin
were the most frequently used agents and ciprofloxacin/
rifampicin and clindamycin for oral treatment. In 44
staphylococcal infections (40%), rifampin was used in
combination therapy at a median dose of 1,200 mg/day.
The choices were culture based.
For pseudomonal infection, parenteral therapy con-
sisted of ceftazidime (n=5), cefepime (n=4), imipenem
(n=2), piperacillin (n=1) and polymyxin B (n=1). Seven
episodes were treated by oral ciprofloxacin 500–750 mg
b.i.d. from the start. Thirteen episodes revealed a combined
initial parenteral antimicrobial treatment for P. aeruginosa.
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Including rifampin treatment for S. aureus, 50 episodes
(38%) were treated with a combination therapy during the
majority of the antibiotic administration time. Three recur-
rent P. aeruginosa strains (3/20; 15%) became resistant to
one of the antimicrobial agents used during initial
treatment (twice to ciprofloxacin and once to imipe-
nem). Except for one case there was no ciprofloxacin
resistance among pseudomonal isolates at the beginning
of therapy.
Outcomes
Overall, 100 episodes (76%) remained in remission after a
median active follow-up time of 4.0 years (range 1.5–
13 years). Stratified by the pathogen, a tendency for a lower
remission rate was found for pseudomonal infections as
compared to S. aureus (12/20 vs 88/111; p=0.06). This was
similar when P. aeruginosa was compared with MRSA
alone (12/20 vs 30/37; p=0.08) (Table 1).
We further stratified remission rate according to the type
of infection. In all three groups of infection, P. aeruginosa
tended towards a lower remission rate than S. aureus, but
none of these results were statistically significant: 2/5 vs
20/25 [odds ratio (OR) 0.2, p=0.1] for osteomyelitis
without implant, 2/3 vs 3/4 (OR 0.7, p=1.0) for septic
native arthritis and 8/12 vs 61/78 (OR 0.5, p=0.5) for
implant-related infections as a group. Of note, among the
seven episodes of pseudomonal infections treated with oral
ciprofloxacin from the start, five were cured and two failed
to respond. This proportion was not different from P.
aeruginosa episodes treated with initial parenteral therapy
(5/7 vs 6/13; p=0.58).
Multivariate analysis
Because of the heterogeneity of the study population and
differences in crude group comparison between MRSA and
P. aeruginosa infections (Table 1), we performed two
multivariate logistic regression analyses to adjust for this
case mix. The first analysis compared P. aeruginosa with S.
aureus as a group and the second P. aeruginosa with
MRSA.
No demographic or therapeutic variable showed a
significant association with remission in either of the
multivariate analyses, although pseudomonal infection
tended towards a lower remission rate with an OR of 0.4
(p=0.08)(Table 2). While the number of surgical interven-
tions tended to be less associated with remission, the
duration of antibiotic treatment did not influence outcome.
Less than six weeks of total antibiotic treatment had the
same outcome as six–12 weeks [OR 0.8, 95% confidence
interval (CI) 0.3–2.6] or more than 12 weeks (OR 0.4, 95%
CI 0.1–1.7). Our statistical model yielded a non-significant
goodness-of-fit test (p=0.4; p=0.2 for MRSA comparison)
and a receiver-operating characteristic (ROC) curve value
of 0.72 (ROC curve value 0.83 for MRSA comparison),
Table 1 Group comparisons
between osteoarticular infec-
tions (P. aeruginosa vs S. aureus
and P. aeruginosa vs MRSA)
Group comparisons were per-
formed with the Wilcoxon rank
sum test, Fisher’s exact test or
the χ2 test, as appropriate
MRSA methicillin-resistant S.
aureus
aOnly statistically significant p
values ≤0.05 (two-tailed) are
displayed
bDiabetes mellitus, dialysis, can-
cer, Child class C cirrhosis,
steroid medication
All types of osteoarticular infections MRSA P. aeruginosa S. aureus
n=131 n=37 p valuea n=20 p valuea n=111
Patients
Female gender 22 0.03 6 47
Median age 76 years 0.02 61 years 64 years
Immunosuppressionb 7 0.04 9 28
Infection
Arthroplasty infections 14 3 35
Presence of abscess 11 8 41
Bacteraemic infection/sepsis 10 3 28
Antibiotic treatment
Median duration of antibiotics 58 days 87 days 46 days
Combination therapy 20 13 37
Surgical treatment
Median no. of surgical interventions 2 2 2
Median delay infection-debridement 9 days 7 days <0.01 32 days
Removal of implant 27 18 65
Reinsertion of a new implant 11 3 23
Outcomes
Remission 30 12 88
Median length of hospital stay 54 days 23 days 42 days
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highlighting an acceptable appropriateness of our final
models.
Discussion
Formally, we report a trend towards a lower remission rate
for orthopaedic infections due to P. aeruginosa compared to
S. aureus or to MRSA with an adjusted OR of 0.4 for
remission (2.5 for failure) in multivariate analysis. Although
this result was formally statistically insignificant, we detected
this tendency in all analyses performed.
Our failure risk of 24% is congruent with the 20%
[12], 21% [13], 25% [27], 27% [14] or 30% [9] failure
rates reported for pseudomonal osteoarticular infections,
although lower (5% [11]; 7% [21]) or higher failure rates
ranging from 33% [23], 35% [24], 38% [22] to 39% [15]
also exist in small case series from the 1980s. Develop-
ment of resistance among failure cases to the antimicrobial
agents used during therapy occurred in 15%, which is
congruent with the 13–24% risk after a prolonged
antibiotic monotherapy during three–four months [9, 24].
Hence, we exclude a major setting bias. The only
particularity of our study population is the relatively small
proportion of haematogenous infections due to S. aureus
(2 of 111), which has been reported more frequently in
another tertiary centre of Switzerland [33].
Of note, infections due to P. aeruginosa benefited from
the same median number of surgical interventions and an
enhanced median duration of 87 days of antibiotic
administration compared to 46 days for S. aureus and still
tended towards more treatment failures. Conversely, dura-
tion of post-debridement antibiotic administration was
unrelated to remission. Less than six weeks of antibiotic
treatment yielded the same remission as six–12 or more
than 12 weeks. Our data suggest that the tendency towards
a lower remission rate in pseudomonal osteoarticular
infections cannot be compensated for by simple prolonga-
tion of post-debridement antibiotic therapy. This finding is
congruent with recent retrospective data suggesting that a
total antibiotic duration of maximally six weeks post-
debridement [3, 16, 20, 34], or regimens with an early
switch to oral antibiotics with good oral bioavailability and
bone penetration [11], are as effective as prolonged
parenteral regimens [14, 35]. Longer treatment durations,
e.g. for more than three months [9, 14, 20, 33] or longer
Table 2 Variables associated with remission in logistic regression analysis
Comparison of P. aeruginosa vs MRSA Comparison of P. aeruginosa vs S. aureus
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
Age 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
Age >70 years compared to ≤70 years 2.9 (0.9–10.0) 2.3 (0.5–9.0) 1.2 (0.5–2.8) 0.7 (0.2–2.0)
Immunosuppressiona 0.3 (0.1–0.8) 0.2 (0.1–1.4) 0.4 (0.2–1.1) n.a.
Arthroplastyb infection n.a. n.a. 1.0 (0.4–2.4) n.a.
Implant-relatedc infection 2.5 (0.7–9.6) 1.8 (0.2–15.0) 1.2 (0.5–3.1) 1.4 (0.5–4.1)
Infection due to P. aeruginosa 0.4 (0.1–1.2) 0.4 (0.1–2.0) 0.4 (0.1–1.1) 0.4 (0.1–1.2)
Bacteraemic disease/sepsis 1.3 (0.3–5.3) n.a. 0.5 (0.2–1.1) n.a.
Presence of abscess 0.5 (0.1–1.5) n.a. 0.7 (0.3–1.5) n.a.
Duration of antibiotic treatment 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
6–12 weeks compared to ≤ 6 weeks 0.7 (0.2–2.8) 1.2 (0.3–5.9) 0.8 (0.3–1.9) 0.8 (0.3–2.6)
>12 weeks compared to ≤ 6 weeks 0.4 (0.1–1.9) 1.9 (0.1–18.0) 0.5 (0.2–1.4) 0.4 (0.1–1.7)
Combined antibiotic therapy 1.2 (0.2–7.7) n.a. 0.9 (0.4–2.4) 1.2 (0.4–3.4)
Delay infection-curative surgery 1.0 (1.0–1.0) n.a. 1.0 (1.0–1.0) n.a.
No. of surgical interventions n.a. n.a. n.a. n.a.
2–3 interventions compared to 1 0.8 (0.2–3.8) 0.7 (0.1–3.8) 0.6 (0.2–1.6) 0.6 (0.2–1.9)
>3 interventions compared to 1 0.1 (0.1–0.7) 0.1 (0.1–0.9) 0.3 (0.1–0.8) 0.3 (0.1–1.2)
Statistically significant results are displayed in boldface
CI confidence interval, n.a. not included in the final model or not analysed due to small sample size
a Diabetes mellitus, dialysis, cancer, Child class C cirrhosis, steroid medication
b Peri-prosthetic joint infections
c All implants without prosthetic joints
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[13], did not enhance remission when compared in the
literature. Dan et al. treated 22 cases of pseudomonal
osteomyelitis with oral ciprofloxacin with various durations
ranging from four to 12 weeks. Remission rates remained
the same or were even enhanced with short regimens (95%)
[11].
We cannot comment on the effect of combination
antibiotic therapy for pseudomonal bone and joint infec-
tions, since few of our episodes had been treated with
monotherapy. Although a more favourable outcome of
combined regimens is still under debate for severe
pseudomonal infections such as bacteraemia [7] or pneu-
monia [7], so far no study could really provide convincing
evidence for the benefits of a targeted combined regimen
for these infections once the results of the susceptibility
testing became available, let alone for osteoarticular
infections. Indeed, orthopaedic and infectious diseases
studies reporting a dual therapy for P. aeruginosa [13, 14]
seem to have similar remission incidences than reports with
single-agent treatment [15, 26]. In one randomised com-
parative trial, seven cases of biopsy-proven P. aeruginosa
osteomyelitis were treated with oral ciprofloxacin, and six
patients received a standard parenteral therapy including an
aminoglycoside plus an antipseudomonal beta-lactam dur-
ing six–eight months. Although it appeared that patients on
standard therapy did better (two vs four failures), the
difference was statistically insignificant and numbers were
too small to permit a valid evaluation [13, 25]. In another
randomised study comparing oral ciprofloxacin to parenteral
ceftazidime and amikacin, Gentry and Rodriguez reported
equal efficacy of the regimens (77% remission vs 79%) [27].
Our study has limitations: (1) It was a retrospective,
single-centre study with a small and heterogeneous popu-
lation. The small sample size may hide differences that
would have been seen if the analyses had been performed
with a larger patient population. However, such a sample
size has never been achieved for osteoarticular infections
due to P. aeruginosa to the best of our knowledge.
According to our estimation, a study population of at least
120 P. aeruginosa patients would be required. (2) Recur-
rences of osteomyelitis after several years, if not decades,
have been reported [36] and there is no internationally
accepted minimal follow-up duration. In the literature,
minimal follow-up times range from three [16] to
six months [21, 25, 26] or one [12, 22, 23] to two years
[9, 10]. Hence, we consider our individual minimal and
median follow-up times of 1.5 and four years as a strong
point of our study. (3) Patients with failures treated in
another hospital may have been undetected. However,
Geneva University Hospitals are by far the largest and
only public hospitals in the area; we therefore consider this
possibility as low. (4) The completeness of initial surgical
debridement as well as the consideration of tissue vascu-
larity and bone necrosis are of paramount importance [23].
Surgeons know how extensively they had performed this
debridement. There are no retrospective possibilities to
estimate the completeness of such a debridement. (5)
Staphylococcal small colony variants are associated with
persistence of bone infections [2]. We could not assess their
presence, since our specimens had not been stored. (6)
Despite adjustment for case mix, we cannot completely
exclude therapeutic decision bias. Patients, who were doing
less well, might have deserved a longer antibiotic treatment.
Likewise, patients infected due to P. aeruginosa may have
special circumstances that explain this unusual pathogen.
Indeed, a large part of our Pseudomonas cases were due to
open fractures. (7) The period of data collection is from 1996
to 2009. During this period, surgical technique and knowl-
edge about osteoarticular infections might have evolved.
Conclusions
Despite a similar number of surgical interventions and a
trend towards longer antibiotic treatment, osteoarticular
infections due to P. aeruginosa may tend towards a lower
remission rate than infections due to S. aureus or MRSA.
This assumption has existed for 20 years but has not yet
been proven [37]. Our single-centre study warrants
confirmation in large multicentre cohorts. If such larger
databases confirm a worse outcome for P. aeruginosa
osteoarticular infections, specific research on treatment
strategies and prevention is needed. In today’s recommen-
dations, only the choice of the antimicrobial agent [38] is
pathogen dependent, but not its duration or the surgical
approach, with a few exceptions for tuberculosis, fungal
infection or nocardiosis [39].
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